Savara (NASDAQ:SVRA) Shares Down 5.1% – Should You Sell?

Shares of Savara Inc. (NASDAQ:SVRA) fell 5.1% on Tuesday . The company traded as low as $6.05 and last traded at $6.0070. 901,501 shares were traded during trading, a decline of 43% from the average session volume of 1,587,894 shares. The stock had previously closed at $6.33.

Wall Street Analyst Weigh In

SVRA has been the topic of several research analyst reports. Guggenheim reaffirmed a “buy” rating on shares of Savara in a research report on Tuesday, December 23rd. UBS Group set a $10.00 price target on shares of Savara in a report on Tuesday, December 23rd. Wells Fargo & Company lifted their price objective on shares of Savara from $7.00 to $9.00 and gave the company an “overweight” rating in a report on Thursday, December 18th. Wall Street Zen raised shares of Savara from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th. Finally, Citigroup reaffirmed an “outperform” rating on shares of Savara in a research report on Thursday, October 23rd. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $9.13.

Savara Trading Down 5.2%

The company has a current ratio of 7.65, a quick ratio of 7.65 and a debt-to-equity ratio of 0.32. The company has a fifty day moving average price of $5.27 and a 200-day moving average price of $3.76. The firm has a market cap of $1.22 billion, a price-to-earnings ratio of -11.33 and a beta of 0.22.

Savara (NASDAQ:SVRA) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.01). As a group, research analysts expect that Savara Inc. will post -0.45 EPS for the current year.

Hedge Funds Weigh In On Savara

Several institutional investors have recently modified their holdings of SVRA. VR Adviser LLC increased its holdings in Savara by 172.7% in the second quarter. VR Adviser LLC now owns 8,884,263 shares of the company’s stock valued at $20,256,000 after buying an additional 5,626,624 shares during the last quarter. Bain Capital Life Sciences Investors LLC boosted its position in shares of Savara by 20.8% during the 1st quarter. Bain Capital Life Sciences Investors LLC now owns 17,600,621 shares of the company’s stock worth $48,754,000 after acquiring an additional 3,035,164 shares in the last quarter. Frazier Life Sciences Management L.P. increased its holdings in shares of Savara by 32.4% in the 1st quarter. Frazier Life Sciences Management L.P. now owns 11,462,301 shares of the company’s stock valued at $31,751,000 after acquiring an additional 2,801,922 shares during the last quarter. Rosalind Advisors Inc. raised its position in shares of Savara by 50.7% during the 3rd quarter. Rosalind Advisors Inc. now owns 4,000,000 shares of the company’s stock worth $14,280,000 after acquiring an additional 1,345,056 shares in the last quarter. Finally, Millennium Management LLC acquired a new stake in shares of Savara during the 3rd quarter worth about $3,014,000. Institutional investors and hedge funds own 87.93% of the company’s stock.

About Savara

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.